Replimune (REPL) Group presented two posters highlighting data updates for RP1 at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting taking place May 30-June 3 in Chicago. The poster included an analysis from the IGNYTE clinical trial of RP1 plus nivolumab in the cohort of anti-PD-1 failed melanoma patients. In the trial, the objective response rate was 32.9% using RECIST 1.1. The complete response rate was 15.0% and landmark overall survival rates at 1, 2, and 3 years were 75.3%, 63.3%, and 54.8% respectively. Median OS has not been reached. Patients experienced numerically higher objective response rates after receiving deep injections compared with superficial injections only. Deep responses were observed in injected and non-injected lesions. The ORR by injection type using RECIST 1.1 was 29.8% when only superficial lesions were injected, 42.9% for deep/visceral plus superficial injections injected, and 40.9% when only deep/visceral lesions were injected. There was a greater than or equal to30% reduction in 93.6% of injected lesions and 79.0% of non-injected lesions. Liver and lung injections had a tolerable safety profile. No bleeding events were reported after liver injection. Lung injections were associated with low rates of pneumothorax events, which were typically of low grade and manageable. Overall, these data support the safety and efficacy of deep/visceral injections and demonstrate the development of a robust systemic anti-tumor response following treatment with RP1 plus nivolumab.